Bach Pharma, Inc. Is Dedicated To The Development Of New Therapeutics For The Treatment Of Life - Threatening Neurodegenerative Diseases.

Bach Pharma, Inc., a privately held company, is a global leader in the development of revolutionary phthalazinedione-based therapeutics to treat life-threatening diseases. Bach’s lead program is targeting degenerative neurological illnesses with the goal to dramatically improve patients' lives and reduce the cost of global health care.

The company's lead candidate, GVT®, is a novel cytoprotective agent with promising powerful anti-oxidant and anti-inflammatory properties. GVT has the potential to treat serious diseases of the central nervous and immune systems, as many are associated with oxidative stress and inflammatory pathways.

 

Recent Events

Northeast ALS Consortium
NEALS
(www.alsconsortium.org)
The 15th Annual NEALS Meeting October 5th to 7th 2016
Opal Sands Resort, Clearwater Beach, Florida

Kelly Blackburn, Bach Pharma CEO, will present a poster on Bach's research on amyotrophic lateral sclerosis (ALS)

Board of Directors Meeting:

North Andover, MA
October 15, 2016, 9:00 am - 3:00 pm
800 Turnpike St, Suite 300
North Andover, MA 01845

About Bach Pharma

Bach Pharma, Inc., (BACH), a privately held pharmaceutical company is a global leader in the development of revolutionary phthalazinedione-based therapeutics...

Science

Bach Pharma is targeting serious and life threatening diseases in which oxidative stress plays a role. This includes neuroimmuno-degenerative illnesses...

Clinical Programs

AEOL 10150 has already performed well in animal safety studies, been well-tolerated in two human clinical trials, demonstrated efficacy in two species in acute radiation...